Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...

Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shock Hennigsdorf/Berlin, November 13, 2025 – 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) today announced the ...

Telitacicept is a dual inhibitor of both B-lymphocyte stimulator and a proliferation-inducing ligand, cytokines that promote B cell survival and production of pathogenic galactose-deficient IgA1.

A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

Cancer treatments can exert cardiotoxic effects, but screening and monitoring can detect and minimize cancer therapy-related ...

Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.

The results of high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.

The benefits are observed across patient subtypes and potentially offer the chance to avoid dialysis and implement a new standard of care.

Empagliflozin therapy was associated with improved kidney outcomes regardless of diabetes, HF, cause of kidney disease, or severity of kidney disease.

The report further notes that structural abnormalities in the GBM, as seen in Alport syndrome, may predispose patients to ...

Cardiologists need to know how to recognize and manage the cardiac effects that can arise from SARS-CoV-2 infections or COVID ...